Sign In
Buy LLY
$1,116.11
-5.06 (-0.451%)
At Close: Aug 04, 2026
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
10:01am, Friday, 31'st Jul 2026
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Beyond The Megacaps: What To Watch In Eli Lilly, Sandisk, SpaceX Earnings | IBD
07:00am, Friday, 31'st Jul 2026
IBD's Alexis Garcia and Ed Carson preview key upcoming earnings reports from Eli Lilly, Sandisk and SpaceX. Check out our daily newsletter!
BankChampaign National Association Buys New Stake in Eli Lilly and Company $LLY
04:03am, Friday, 31'st Jul 2026
BankChampaign National Association acquired a new position in Eli Lilly and Company (NYSE: LLY) during the first quarter, according to its most recent filing with the Securities and Exchange Commissio
Lilly Boosts Diabetes and Obesity Capacity With $750 Million Deal
11:19am, Thursday, 30'th Jul 2026
Eli Lilly (LLY) and contract manufacturer Resilience will invest $750 million to expand pharmaceutical production in the Cincinnati region, adding Lilly's KwikP
Watching Eli Lilly; Hearing Investor Business Daily SwingTrader Sells Stock
10:15am, Thursday, 30'th Jul 2026
� 2025 Benzinga.com. Benzinga does not provide investment advice.
Lilly, Resilience to invest $750 million in US drug manufacturing expansion
08:58am, Thursday, 30'th Jul 2026
Drugmaker Eli Lilly and privately held contract manufacturer Resilience will invest $750 million to expand pharmaceutical manufacturing capacity in the U.S. and strengthen the domestic medicine
Jim Cramer: Eli Lilly Is A 'Good Company,' But Doesn't 'Really Care For' This Quantum Stock
08:15am, Thursday, 30'th Jul 2026
On CNBC's “Mad Money Lightning Round,” Jim Cramer said Astera Labs, Inc. (NASDAQ:ALAB) is a buy.
These 2 stocks are worth watching amidst ongoing stock market rotation
11:05pm, Wednesday, 29'th Jul 2026
The benchmark S&P 500 index has spent the summer coiled in a tight range just below its “short-term moving averages,” currently down over 3% from its June high. Beneath this surface-level stillnes
Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now
05:00pm, Wednesday, 29'th Jul 2026
But is that performance sustainable?
The Week Ahead: Jobs Data, Top 10 Earnings Reports to Watch
03:27pm, Wednesday, 29'th Jul 2026
Next week keeps up the earnings barrage, a heavy dose of earnings from some of the market's largest companies, led by pharma giant Eli Lilly (LLY) and industrial bellwether Caterpillar (CAT).
Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?
11:01am, Wednesday, 29'th Jul 2026
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Forget Weight Loss Drugs: Here's Another Reason to Buy Eli Lilly Stock
08:06am, Wednesday, 29'th Jul 2026
Eli Lilly is purchasing a psychedelic drug developer biotech, AtaiBeckley. That'll build out its mental health portfolio substantially.
Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients
07:30am, Wednesday, 29'th Jul 2026
Amgen wants a slice of the weight loss drug market. Its candidate for capturing that market share might not be up to the task.
Johnson & Johnson vs. Eli Lilly: Reliable Stability vs.
07:24am, Wednesday, 29'th Jul 2026
Eli Lilly currently displays stronger upward momentum in top-line growth, whereas Johnson & Johnson maintains a higher but flatter overall baseline. Over roughly the last eight quarters, the two compa
Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.
05:00am, Wednesday, 29'th Jul 2026
One of Cathie Wood's funds just sold some AtaiBeckley shares. It also bought some Compass Pathways shares.
